Endothelial Exosomes

Overview

Parent Cell: Akira Endothelial Cells differentiated from UCT-WJ-MSCs | Angiogenic and anti-inflammatory growth factors and miRNAs for vascular repair and regeneration

Related: Exosomes Overview • Endothelial Cells

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

What Are Exosomes?

Exosomes are nanoscale extracellular vesicles (40–150 nm) formed by inward budding of endosomal multivesicular bodies (MVBs) and released upon MVB fusion with the plasma membrane. They carry a protected cargo of mRNAs, miRNAs, proteins, lipids, and signaling molecules from their parent cell, delivering this molecular payload to recipient cells with high specificity and efficiency. Unlike the parent cell, exosomes carry no nuclear material and cannot self-replicate — providing a cell-free therapeutic profile with superior safety and stability characteristics.

The Akira Endothelial Exosomes are derived from endothelial cells (ECs) produced by VEGF-driven directed differentiation of UCT-WJ-MSCs. Endothelial identity is confirmed by co-expression of CD31, VE-Cadherin, vWF, and eNOS. Endothelial-derived exosomes are the primary intercellular communicators of vascular biology — regulating angiogenesis, vascular tone, endothelial barrier integrity, and thrombosis through a highly specialized cargo of angiogenic miRNAs and growth factors.

miR-126 is the signature endothelial miRNA, uniquely expressed at high levels in endothelial cells and their exosomes, where it regulates VEGF signaling, endothelial barrier function, and vascular homeostasis. This preparation is particularly relevant to research in vascular disease, ischemia, diabetic vasculopathy, pulmonary hypertension, and any condition characterized by endothelial dysfunction or impaired angiogenesis.^[1]

Mechanism of Action

Angiogenesis & Neovascularization: VEGF-A and VEGF-C cargo drive endothelial proliferation, migration, and tube formation — the core steps of angiogenesis. Ang-1 recruits pericytes to stabilize nascent vessels, preventing the leaky, dysfunctional vasculature associated with VEGF-only angiogenic responses. FGF-2 drives arteriogenesis, promoting the formation of mature, high-flow collateral vessels in chronically ischemic tissue.

Endothelial Barrier Restoration: miR-126 maintains VE-Cadherin expression and tight junction integrity in endothelial cells, restoring barrier function in inflamed or damaged vessels. This is critical in conditions of pathological vascular permeability — sepsis, ARDS, diabetic retinopathy, and inflammatory vascular disease. eNOS-associated cargo promotes NO production, maintaining vasodilation and anti-thrombotic endothelial tone.

Anti-Thrombotic & Anti-Inflammatory Vascular Signaling: eNOS activation via exosome cargo reduces platelet aggregation and leukocyte adhesion to the endothelial surface. miR-146a suppresses endothelial NF-κB activation, reducing ICAM-1, VCAM-1, and E-selectin expression — the adhesion molecules that recruit inflammatory cells to the vessel wall. This endothelial anti-inflammatory activity is relevant to atherosclerosis, vasculitis, and systemic inflammatory conditions.

Lymphangiogenesis & Lymphatic Drainage: VEGF-C is the primary lymphangiogenic factor, stimulating VEGFR-3 on lymphatic endothelial cells to drive lymphatic vessel growth. This is relevant to lymphedema research — a common complication of cancer treatment and a significant source of morbidity. Restoration of lymphatic drainage reduces chronic tissue edema and improves tissue homeostasis.^[2]

Key Molecular Cargo

Potential Applications

• Peripheral Arterial Disease: VEGF-A and FGF-2 collateral angiogenesis; Ang-1 vessel stabilization.
• Diabetic Vasculopathy: Endothelial barrier restoration via miR-126; eNOS-mediated NO production.
• Pulmonary Hypertension: Endothelial repair via VEGF/Ang-1; anti-inflammatory miR-146a.
• Lymphedema: VEGF-C-driven lymphangiogenesis; lymphatic endothelial cell proliferation.
• Atherosclerosis Research: miR-146a and miR-126 endothelial anti-inflammatory signaling.
• Wound Bed Vascularization: Multi-factor angiogenic cargo restores perfusion to ischemic wound beds.
• Retinal Vascular Disease: VEGF regulation via miR-126; endothelial barrier maintenance in retinal vasculature.
• Sepsis-Related Vascular Injury: Barrier restoration via VE-Cadherin/miR-126; anti-inflammatory NF-κB suppression.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical & Preclinical Evidence

The evidence base for this preparation is preclinical and mechanistic rather than product-specific clinical trial data. Endothelial progenitor cell transplantation has shown angiogenic benefit in critical limb ischemia,^[3] and combined endothelial/smooth-muscle cell therapy derived from stem cells has demonstrated efficacy in critical limb ischemia models.^[4] Endothelial progenitor cell status has independently been linked to major amputation risk after angioplasty in critical limb ischemia patients — underscoring the clinical relevance of restoring endothelial function in this population.^[5] See the Akira Endothelial Cells guide for whole-cell trial data from the same lineage, including hindlimb ischemia and hypertensive rat model results.